SlideShare a Scribd company logo
1 of 80
Download to read offline
Summon Chomchai, MD, MPH
         Department of Preventive and Social Medicine
Faculty of Medicine Siriraj Hospital, Mahidol University
   A 55 year-old-man
   Found unconscious at home 1 hour PTA
   1-2 hours PTA: He was seen eating Kratom and
    drank ethanol
   At the ED:
   P 96/min, R 12/min, BP 100/70 mmHg, O2 Sat 95%
    at room air
   GCS: E1V1M1, pupils 2 mm
   CVS and Chest: WNL, no secretion sound
   Normal skin and mucosa
   NS: Comatose, reflexes: 2+, plantar reflexes:
    fleoxor responses
   0.4 mg of Naloxone was given with no
    response
   He was treated with supportive (IV fluid,
    oxygen by canular and monitoring)
   He woke up 10 hours after presentation
   Admitted to ingested one handful of Kratom
    and one bottle of whiskey
 Mithragyna  Speciosa Korth
 A plant used in Thailand and
  Malaysia
 Scheduled to be illegal in
  Thailand, Malaysia, Myanmar and
  Australia
 Increasing popularity as a drug of
  abuse
     Clinical Toxicology (2008) 46, 146–152
   Mithragynine and 7-hydroxymithragynine
   Unknown human pharmacokinetics
   Agonists of delta and delta opioid receptors:
    Analgesia, euphoria and respiratory
    depression
   Agonist to presynaptic alpha-2 adrenergic
    ,adenosine and serotonin receptors

      Clinical Toxicology (2008) 46, 146–152
   Rat pharmacokinetic study:
    ◦ Peak plasma level:1.2-1.8 hour
    ◦ Elimination half-life: 3.86-9.43 hours
    ◦ Volume of distribution: 37.9-89.5 L/kg


    ◦ Clinical Toxicology (2008) 46, 146–152
   Dose-dependent neuropsychiatric symptoms
   Onset 10-15 minutes; duration 1 hour
    ◦ Low dose: Stimulation: hypertension, tachycardia,
      tremor at low dose
    ◦ High dose: Opioid effects in high doses
   Nausea, vomiting and diarrhea are commonly
    reported

   Clinical Toxicology (2008) 46, 146–152
   It is used in workers in Thailand
   In 2003, at least 221600 people were
    estimated to use Kratom in Thailand
    ◦ ~2% of Southern Thailand population
   Purposes:
    ◦ Abuse: increase work endurance
    ◦ Medicinal use: treatment of chronic pain, cough,
      weight control
    ◦ Reports of using kratom for treating opioid
      withdrawal
          Substance Use & Misuse (2006), 42:2145–2157
   Age of first uses: 20-40 years
   Regular users: use because of condonation
    by family and peers as opposed to other
    ‘hard drugs’
   Chewing leaves, drinking tea, smoking dry
    leaves
   Very bitter taste; usually wash the taste with
    water, energizing beverages and palm juice
   Adverse effects perceived by users:
    constipation, tremor and headahce
        Substance Use & Misuse (2006), 42:2145–2157
   61% of regular uses believe that they are
    addicted to Kratom
   Withdrawal symptoms
    ◦ Inability to work
    ◦ Pain the the back, legs and muscles
    ◦ Crave
   Other reported withdrawal symptoms: Yawn,
    rhinorrhea, myalgia, arthralgia and diarrhea
        Substance Use & Misuse (2006), 42:2145–2157
   Rarely reported
   2 case in Pubmed
   1 case with unconsciousness and seizures
   1 case of seizures
   AMS for 30 hours
   Confirmed mithragynine detection in urine by
    HPLC-ESI/MS/MS
   No known long-term effects
        J Med Toxicol. 2010 Apr 22.
        Addiction. 2008 Jun;103(6):1048-50.
   Supportive and symptomatic care
   Naloxine may be considered in cases with
    respiratory depression

   J Med Toxicol. 2010 Apr 22.
   A 12-year-old girl was brought to the
    emergency room due to alteration of
    consciousness.
   Her parents gave the history of using an
    over-the-counter antitussive drug, a small
    yellow coated tablet, for illicit purposes.
   Her habit changed from gradual to
    progressive increase in the dosage of drug
    use, and from occasional with a few tablets at
    a time to daily doses in order to gain the
    desired effect of euphoria
   Six hours prior to hospitalization, the patient took 26 tablets
    of dextromethorphan (Romilar).
   She reported of feeling sleepy, with nausea and abdominal
    discomfort.
   Her father noted that she became increasingly confused and
    brought her to the emergency department (ED).
   At the ED, vital signs BP117/70 mmHg, P 122 / min, R 20/
    min, T38.2o C.
   The patient appeared drowsy with Glascow coma scale of 15
    (E4V5M6)
   She was responsive and verbalized with notably slow speech.
   Nystagmus was seen, Fundoscopic examination was normal
           J Med Assoc Thai 2005; 88(Suppl 8): S242-5
   Non-opioid synthetic analog of codeine
    ◦ dextro-isomer of levorphanol
   Actions are modulated by central sigma receptor
    binding sigma receptors
   Unlike most opioids, the drug is devoid of activity
    at mu and delta receptors
   Typical adult and pediatric doses (>12 years of
    age) of DM range from 60 to 120 mg/day in
    divided doses
   At clinical doses, the drug produces no euphoriant,
    analgesic, or dependence-producing effects

                     J Am Pharm Assoc. 2009;49:e20–e27
   Metablozied by CYP 2D6 to dextrophan
    ◦ noncompetitively antagonize the N-methyl-D-aspartate
     (NMDA) receptor and serotonin release
    ◦ Euphoria, hyperactivity and hallucination
   In general, acute overdose of dextromethorphan
    causes nausea, vomiting, hyperexcitability,
    restlessness, hallucination, dizziness, drowsiness,
    ,lethargy, slurred speech, mydriasis, euphoria,
    tachycardia, hypertension and urinary retention.
   The classical opioid effects such as respiratory
    depression and miosis are not commonly seen


                      J Am Pharm Assoc. 2009;49:e20–e27
J Am Pharm Assoc. 2009;49:e20–e27
   Minimal: 80-100 mg
   Common: 200-400 mg
   Heavy: 600-1500 mg
   It may be ingested or snorted
   Vivid visual hallucinations and complete body
    analgesia
   Mild withdrawal symptoms that are similar to those
    of opiate withdrawal

      http//:www.erowid.org/chemicals/dxm.
   Clinical diagnosis
   Urine test: false positive for PCP

        J Emerg Med. 2000;18:379-381.
   Gastric decontamination
   Naloxone therapy: shown to be effective
    when used in children and for the specific
    indications of hyperexcitability, altered
    mental status or respiratory depression
        Am J Emerg Med. 1991;9:237-238.
   A 18 y/o woman was brought in because of
    alteration of consciousness with a container of
    abamestin 1.8% W/V beside her
   BP 102/60 mmHg, P 64/min, R 26/min, O2sat 90%
    @ room air
   E1V1M2, pupils 3mm not reactive to light, normal
    skin and mucosa
   CVS & Chest: WNL
   Abdomen: Soft normal bowel sound
   NS: Flaccid tone, reflexes: 1+ upper extremities,
    absent: lower extremities
   Abamectin is a potent
    antihelmintic, insecticide,
    and miticide
   Derived from Strepto-myces
    avermitilis (species of
    Actinomyces)
   Abamectin: a mixture of
    avermectins containing
    >80% avermectin B1a and
    <20% avermectin B1b
    ◦ Similar biological and
      toxicological properties
   Toxic effects of abamectin are usually seen
    after oral ingestions
   May be absorbed dermally
   Following their absorption, maximum
   Serum concentrations peak 2.7 to 5 hours
    after oral dosing
   Elimination half-life was 2.8 to10 hours
    among healthy volunteers
    ◦ Largely excreted into the bile and feces
        Clin Toxicol (Phila). 2007;45(3):299-300.
   CNS symptoms such as incoordination,
    tremor, lethargy, excitation, and mydriasis via
    GABA agonistic effect
   Deaths related to Abamectin ingestion are
    commonly a result of respiratory failure
   From our experience: shock and status
    epilepticus

        Clin Toxicol (Phila). 2007;45(3):299-300.
   Only one study in the literature by Chung et al
   a significant correlation between the ingested
    abamectin dose and clinical severity
    ◦ For asymptomatic and mild poisoning, the
      average ingested dose was 23.0 mg/kg
    ◦ Average dose for severely poisoned patients was
      100.7 mg/kg ~ 280 mL
    ◦ CNS and gastrointestinal effects:diarrhea, nausea,
      vomiting, AMS, dizziness and weakness
          Ann Emerg Med. 1999 Jul;34(1):51-7.
   Airway protection
   Hypotension: intravenous fluid and
    vasopressor

      Clin Toxicol (Phila). 2007;45(3):299-300.
   Inhibitor of AchE
   Bind to AchE and form a stable compound
   Inactivate AchE molecule inactive
   Once AchE molecules are unavailable,
    continued stimulation
     cholinergic overstimulation
     paralysis
   Signs and Symptoms
     I. Muscarinic or parasympathetic symptoms
       SLUDGE + 3 KILLER Bs
     II. Nicotinic/ganglionic/NM symptoms
       Muscle fasciculations, progressive paralysis and
        respiratory failure.
       Hypertension, tachycardia, pupillary dilatation and
        pallor
     III. CNS symptoms
       Restlessness, tremor, confusion, ataxia, slurred
        speech and seizure.
   Clinical diagnosis
   Cholinesterase level
     Wide normal range
     RBC cholinesterase
       Specific
       Hardly available
     Plasma cholinesterase
       More available
       Non-specific
   Pupils
   Sweating
   Lung sounds: air entry, bronchospasm,
    secretion
   Heart rate
   Blood pressure




              Lancet. 2008 Feb 16;371(9612):597-607.
   Antagonizing muscarininc effects
   Reactivating blocked cholinesterase
   Treatment of muscle hyperstimulation/
    seizures




               Lancet. 2008 Feb 16;371(9612):597-607.
   If the clinical presentation is not clear
    ◦ administer atropine 0.6– 1 mg
   A marked increase in heart rate (more than
    20–25 beats/min) and flushing of the skin
    suggest that the patient does not have
    significant cholinergic poisoning and further
    atropine is not required




                Lancet. 2008 Feb 16;371(9612):597-607.
   Atropine 1.8–3 mg (three to five 0.6 mg vials)
   3-5 minutes after giving atropine, check the
    five markers of cholinergic poisoning(
   A uniform improvement in most of the five
    parameters is required
   The most important parameters are air entry
    on chest auscultation, heart rate, and blood
    pressure


               Lancet. 2008 Feb 16;371(9612):597-607.
   Clear chest on auscultation         Pupils
    with no wheeze                      Lung sounds
   Heart rate >80 beats/min
   Pupils no longer pinpoint
   Dry axillae
   Systolic blood pressure >80
    mmHg




Indicators                           Pitfalls
                    Critical Care 2004, 8:R391-R397
   With no improvement in 3-5 minutes: double dose the
    atropine until the goal is achieved
   Continue doubling the dose each time that there is no
    response
   From a review of 22 surviving patients with OP-poisoning and
    respiratory failure dose of atropine 1-75 mg(mean23.4 mg,
    22.0sd) to clear the lungs, raise the pulse above 80bpm, and
    restore systolic blood pressure to more than 80 mmHg
   Standard textbook therapy will take
    ◦ Up to 1380 mins to mean dose
    ◦ Up to 4440 mins to 75 mg dose



           J Toxicol Clin Toxicol. 2004;42(6):865-75.
           Crit Care. 2004 Dec;8(6):R391-7.
   Infusion of atropine
   Rate per hour = 10-20% loading dose

   Atropine intoxication: agitation, confusion, urinary
    retention, hyperthermia, bowel ileus and
    tachycardia
   With intoxication: stop the atropine infusion and
    check every 30 minnutes
   Once the atropine intoxication subsides restart the
    infusion at the rate 70-80% of the previous rate

                 Lancet. 2008 Feb 16;371(9612):597-607.
   Oximes reactivate acetylcholinesterase
    inhibited by oganophosphorus
   Despite the beneficial effects of pralidoxime,
    its effectiveness (and safety) has been much
    debated
   Meta-analysis of 7 studies of severe OP
    poisoning
   382 patients
   No significant risk or harm in terms of
    ◦ Overall mortality
    ◦ Need of respiratory support
        Crit Care Med. 2006 Feb;34(2):502-10.
Crit Care Med. 2006 Feb;34(2):502-10.
Crit Care Med. 2006 Feb;34(2):502-10.
   A randomized controlled trial studied the effect of
    very-high-dose pralidoxime
   Pralidoxime iodide (2 g loading dose, then 1 g either
    every hour or every 4 h for 48 h, then 1 g every 4 h
    until recovery)
   200 patients with moderate organophosphorus
    poisoning
   The high-dose regimen was associated with reduced
    case fatality (1% vs 8%; odds ratio [OR] 0·12, 95% CI
    0·003–0·90),

   Lancet. 2006 Dec 16;368(9553):2136-41.
   A prospective study on 802 patients self-
    poisoned with chlorpyrifos, dimethoate, or
    fenthion
   Mortality: chlorpyrifos (8.0%), dimethoate
    (23.1%), fenthion (16.2%)
   Endotracheal intubation: chlorpyrifos(15.0%),
    dimethoate (35.2%), fenthion (31.3%)
   Patients poisoned by
    ◦ Diethyl OP pesticide (chlorpyrifos) responded well
      to pralidoxime
    ◦ Dimethyl OP (dimethoate, fenthion) responded
      poorly
                      Lancet. 2005 Oct 22-28;366(9495):1452-9.
                      Neth J Med. 2008 Apr;66(4):146-8.
   Dimethoate-poisoned patients
    ◦ Died sooner than other pesticides
    ◦ Often died from hypotensive shock
   Fenthion poisoning initially caused few
    symptoms but many patients subsequently
    required intubation
        Lancet. 2005 Oct 22-28;366(9495):1452-9.
Lancet. 2005 Oct 22-28;366(9495):1452-9.
   Acephate             Chlorpyriphos Dialifos
   Dicrotophos          Diazinon
                         Dichlofenthion
   Dimethoate
                         Dioxathion
   Fenchlorphos         Fonofos
   Fenitrothion         Isazophos
   Malathion            Isoxathion
   Methamidophos        Mephosfolan
                         Phorate
   Methylparathion
                         Phosalone
   Mevinphos            Phoxim
   Monocrotophos        Quinalphos
   Temephos             Triazophos
   Thiometon
   Trichlorfon


Dimethyl-             Diethyl-
   A double-blind randomised placebo-controlled
    trial of pralidoxime chloride (2 g loading dose over
    20 min, followed by a constant infusion of 0.5 g/h
    for up to 7 d)
   235 patients with organophosphorus insecticide
    self-poisoning
   Pralidoxime reactivated RBC acetylcholinesterase
    significantly
   Mortality was nonsignificantly higher in treatnment
    group: 30/121 (24.8%) vs placebo18/114 (15.8%)

          PLoS Med. 2009 Jun 30;6(6):e1000104.
PLoS Med. 2009 Jun 30;6(6):e1000104.
PLoS Med. 2009 Jun 30;6(6):e1000104.
   Pralidoximes be given to all symptomatic
    patients who need atropine or manifesting
    neuromuscular manifestations
   Pralidoxime chloride
    ◦ Loading dose of 30 mg/kg intravenously over 20
      minutes, followed by an infusion of 8 mg/kg/h
    ◦ Adults: 2 g loading dose followed by 500 mg/h.
   Continue until recovery (12 hours after
    stopping administration of atropine or once
    butyrylcholinesterase increase)

                Lancet. 2008 Feb 16;371(9612):597-607.
   In the cholinergic nervous system, diazepam
    appears to decrease the synaptic release of
    Ach
   In CNS diazepam causes hyperpolarization of
    neurons making them significantly less
    susceptible to cholinergically induced
    depolarization
    ◦ The ultimate result is cessation of propagation of
      convulsions
          BMJ. 2007 Mar 24;334(7594):629-34.
   Overall effects of benzodiazepine: reducing
    anxiety and restlessness, reducing muscle
    fasciculation and seizures, controlling
    agitation
   Indications: patients poisoned with OP
    whenever convulsions, agitation or
    pronounced muscle fasciculation are present
   Doses:
    ◦ Diazepam 5-10 mg (0.05-0.3 mg/kg/dose)
    ◦ Midazolam 5-10 mg (0.15-0.2 mg/kg/dose)
         Lancet. 2008 Feb 16;371(9612):597-607.
   A bipyridium herbicide
   Toxicokinetics
    ◦   Rapid absorption: peak plasma level within 1-2 hours
    ◦   Incomplete absorption: 10-30%
    ◦   Distribute to tissues: Lung, Kidney
    ◦   Elimination: 90% eliminated within 12 -24 hours via kidney (half-life 10-12 hours)
 Ingestion of paraquat leads to
    ◦ Generation of free oxygen radicals
    ◦ Lipid peroxidation
    ◦ Damaging cell membranes and leading to cell death.
   Paraquat is actively taken up into type II
    pneumocytes and renal tubular cells.
   Mild poisoning:
    ◦ Local irritation: vomiting and diarhea
    ◦ Ingestion of less than 20 mg/kg of paraquat ion
    ◦ Full recovery without sequelae
   Moderate to severe:
    ◦   Ingestion of 20-40 mg/kg of paraquat ion
    ◦   GI corrosion, acute tubular necrosis, hepatitis
    ◦   Delayed progressive pulmonary fibrosis
    ◦   Delayed mortality (1-4 weeks) from hypoxia
    ◦   Survivors may have gradual recovery of pulmonary functions over months to years
   Fulminant poisoning:
    ◦ Ingestion of more than 40 mg/kg of paraquat ion Usually die within 1-5 days
    ◦ GI ulceration
    ◦ Acute renal failure, myocardial damage, hepatic failure, pulmonary edema and
      hemorrhage
    ◦ Multiorgran failure, shock
    ◦ 100% mortality regardless of management
   Hart’s Nomogram
   Plasma paraquat level drawn within 28
    hours
   Those with level 3 mg/L at anytime:
    100% mortality
   No fulminant poisoning:
      2.0 mg/L at 4 hr
      0.3 mg/L at 10 hr
      0.1 mg/L at 24 hr




         Eddleston M, Wilks MF, Buckley NA. Qjm 2003;96(11):809-24.
                                                                      61
Method           Sensivitity   Specificity   Positive     Negative
                                             predictive   predictive
                                             value        value

Proudfoot/           0.79          0.89          0.92         0.73
Scherrmann


Hart (50%            0.77          0.92          0.94         0.71
survival line)


Jones(p=0.5)         0.70          0.93          0.94         0.67
   In a study with 53 cases of paraquat
    poisoning
   All patients with urinary paraquat
    concentrations less than 1 µg/ml(no color
    change-pale blue), within 24 h of ingestion,
    survived
   Cases with results more than ++ (navy
    blue; >10 µg/ml) within 24 h following
    ingestion have a high probability of death
      Hum Toxicol1987 Jan;6(1):91-3.
   A study using sodium dithionite test for plasma paraquat
    as a qualitative test in 233 paraquat poisoning patients
   Blood samples were drawn within 12 hours
   Detection limits: concentration ≥ 2 mg/L
       Levels above 2 mg/L are associated with high mortality
        in many studies
       Patients with a plasma paraquat level < 2.0 mg/L have
        the potential for recovery with vigorous treatment

   Sensitivity 0.67
   Specificity 1.0
   Positive predictive value 1.0
    ◦ Am J Med Sci2009 Nov;338(5):373-7.
   Urine should be tested serially for 24 h after
    ingestion
   An early urinary semiquantitative testing may
    underestimate the amount of paraquat
    systemically absorbed

        Crit Rev Toxicol. 2008;38(1):13-71.
   Although quantitative plasma paraquat
    concentrations have a greater predictive
    value, qualitative urine and plasma may
    contribute to a more rapid evaluation of
    prognosis with more availability


           ◦Am J Med Sci2009 Nov;338(5):373-7.
   Activated charcoal/ Fuller’s earth/ bentonite
   Improve survival in animal studies
   Equivocal efficacy in animal studies
   Adsorbent therapy alone has never shown increase survival in human
           Meredith TJ, Vale JA. Hum Toxicol 1987;6(1):49-55.




                                                                         69
   Significant clearance and improved survival shown in canine models
    loaded with LD50 and LD100 dose.
   No systematic study showing that hemodialysis or hemoperfusion is
    efficacious in human
   Possible cause of failure:
       Relatively small amount cleared
       While renal function is still intact, external clearance is smaller than
        renal clearance
       When renal failure develops, pulmonary uptake has already occurred.
   Recommendation: perform charcoal hemoperfusion only if it can be
    started within 4 hours.
      Med J Aust 1991;154(9):617-22.




                                                                                   70
   The most widely investigated and applied aspect of
    specific management is immunosuppressive therapy,
    especially the regimen consisitng of
    ◦ Cyclophosphamide
    ◦ Corticosteriods
   Concepts: Reduction of pulmonary inflammation and
    fibrosis using antiinflammatory and
    immunosuppressive therapy
 Regimen: cyclophosphamide 5
  mg/kg/day and dexamethasone 24
  mg/day for 14 days
 Total cases = 72
 Mortality: treated 20/72(27.8)% vs
  historical control 42/61(68.9%)
     Lancet. 1986 May 17;1(8490):1117-20.
 Another study
 Survival: treated 20/31(64.5%) vs
  historical control 9/14(64.3%)
     Hum Exp Toxicol. 1992 Mar;11(2):129-34.
 A single-blinded randomized clinical trial in
  142 paraquat-poisoned patients, pulse
  therapy reduced mortality in moderate to
  severe poisoning from 53/65(81.5%) to
  38/56(67.9%)
 Pulse therapy included
1. 15 g/kg/day of cyclophosphamide for 2
  days
2. 1 g/day of methylprednisolone for 3 days
 All patients also received dexamethasone
  30mg/day for 14 days
     Am J Respir Crit Care Med. 1999 Feb;159(2):357-60.
   N = 23 cases of paraquat poisoned patients with
    predictive mortality > 50% but < 90% by plasma
    level
   Initial pulse therapy:
    cyclophosphamide (15 mg/kg/day, i.v., 2 days) and
      methylprednisolone (1 g/day i.v., 2 days)
    Followed by dexamethasone 5 mg, i.v., every 6 h until PaO2 >
      80 mmHg
   Randomized cases for repeated pulse therapy if
    PaO2 was < 60 mmHg: 3 days of
    methylprednisolone and 1 day of
    cyclophosphamide
   Mortality rate:
    ◦ control 6/7 = 85.7%
    ◦ Study 5/16 = 31.3% (p=0.027)
         Crit Care Med. 2006 Feb;34(2):368-73.
 A retrospective study in 54 cases
 Significantly higher survival with
  suppression of leucocyte or neutrophil
  counts by at least 10% after the
  initiation of immunosuppressive

    ◦ Journal Of the Chinese Medical Association2009;72(9 supplement):S20-1.
   12 studies using immunosuppressive therapy in
    the management of paraquat poisoning
    ◦ Four non-randomized
    ◦ Six non-randomized comparing historical controls
    ◦ Two randomized controlled trials
   The relative risk of immunosuppressive therapy in
    decreasing mortality with paraquat poisoning
    ◦ 0.55 (95 % CI 0.39- 0.77) for the non-randomized studies
        (comparing historical controls)
    ◦ 0.6 (95 % CI 0.27-1.34) for randomized controlled studies
         Singapore Med J2007 Nov;48(11):1000-5.
   Systematic review
   3 RCT
   Total cases : 164 moderate to severe cases
   Inclusion criteria: Urine navy blue or drak blue and/
    or plasma level in the range of mortality 50-90%
   Interventions: IV cyclophosphamide and
    dexamethasone
   Main outcomes: mortality at the end of follow up
    (at least 30 days post ingestion)
   Results: RR 0.72 (95% CI 0.59 to 0.89)

   Cochrane Database Syst Rev. 2010 Jun 16;6:CD008084.
Cochrane Database Syst Rev. 2010 Jun 16;6:CD008084.
toxbuster@hotmail.com

More Related Content

What's hot

Epilepsy recent advances and existing pharmacotherapy
Epilepsy recent advances and existing pharmacotherapyEpilepsy recent advances and existing pharmacotherapy
Epilepsy recent advances and existing pharmacotherapyDr. Siddhartha Dutta
 
Serotonin syndrome77
Serotonin syndrome77Serotonin syndrome77
Serotonin syndrome77salehsalman
 
SSRIs and Serotonin Syndrome
SSRIs and Serotonin SyndromeSSRIs and Serotonin Syndrome
SSRIs and Serotonin SyndromeTeresa Chahine
 
Prescribing in physiological conditions
Prescribing in physiological conditionsPrescribing in physiological conditions
Prescribing in physiological conditionsDr. Siddhartha Dutta
 
Dexmedetomidine For Pediatric Procedural Sedation
Dexmedetomidine For Pediatric Procedural SedationDexmedetomidine For Pediatric Procedural Sedation
Dexmedetomidine For Pediatric Procedural Sedationshabeel pn
 
Case Studies Clinical pharmacy
Case Studies Clinical pharmacyCase Studies Clinical pharmacy
Case Studies Clinical pharmacyQurat Ul Ain
 
Supportive Care of Cancer
Supportive Care of CancerSupportive Care of Cancer
Supportive Care of CancerChirag Dave
 
Newer Aeds Recommendations And Practice Parameters
Newer Aeds Recommendations And Practice ParametersNewer Aeds Recommendations And Practice Parameters
Newer Aeds Recommendations And Practice ParametersPramod Krishnan
 
Icu delirium 11.8.19
Icu delirium 11.8.19Icu delirium 11.8.19
Icu delirium 11.8.19Allison Boyd
 
Xolair and Cinqair for allergic asthma
Xolair and Cinqair for allergic asthmaXolair and Cinqair for allergic asthma
Xolair and Cinqair for allergic asthmaJoseph DiMasso
 
Sedation & Paralysis in ICU- DR.RAGHUNATH ALADAKATTI
Sedation & Paralysis in ICU- DR.RAGHUNATH   ALADAKATTISedation & Paralysis in ICU- DR.RAGHUNATH   ALADAKATTI
Sedation & Paralysis in ICU- DR.RAGHUNATH ALADAKATTIapollobgslibrary
 
48078289 pharmacology-review-for-nurses
48078289 pharmacology-review-for-nurses48078289 pharmacology-review-for-nurses
48078289 pharmacology-review-for-nursesThania Boquiren
 
Exciting recent advances in neurology
Exciting recent advances in neurologyExciting recent advances in neurology
Exciting recent advances in neurologySudhir Kumar
 
Sedation practices in ICU
Sedation practices in ICUSedation practices in ICU
Sedation practices in ICUAbhijit Nair
 
Parkinson disease Walid Reda Ashour Egypt
Parkinson disease  Walid Reda Ashour EgyptParkinson disease  Walid Reda Ashour Egypt
Parkinson disease Walid Reda Ashour EgyptWalid Reda Ashour
 

What's hot (20)

Epilepsy recent advances and existing pharmacotherapy
Epilepsy recent advances and existing pharmacotherapyEpilepsy recent advances and existing pharmacotherapy
Epilepsy recent advances and existing pharmacotherapy
 
Serotonin syndrome77
Serotonin syndrome77Serotonin syndrome77
Serotonin syndrome77
 
SSRIs and Serotonin Syndrome
SSRIs and Serotonin SyndromeSSRIs and Serotonin Syndrome
SSRIs and Serotonin Syndrome
 
Prescribing in physiological conditions
Prescribing in physiological conditionsPrescribing in physiological conditions
Prescribing in physiological conditions
 
Dexmedetomidine For Pediatric Procedural Sedation
Dexmedetomidine For Pediatric Procedural SedationDexmedetomidine For Pediatric Procedural Sedation
Dexmedetomidine For Pediatric Procedural Sedation
 
Case Studies Clinical pharmacy
Case Studies Clinical pharmacyCase Studies Clinical pharmacy
Case Studies Clinical pharmacy
 
SEIZURES
SEIZURESSEIZURES
SEIZURES
 
Supportive Care of Cancer
Supportive Care of CancerSupportive Care of Cancer
Supportive Care of Cancer
 
Status epilapticus
Status epilapticusStatus epilapticus
Status epilapticus
 
Newer Aeds Recommendations And Practice Parameters
Newer Aeds Recommendations And Practice ParametersNewer Aeds Recommendations And Practice Parameters
Newer Aeds Recommendations And Practice Parameters
 
Sedation
SedationSedation
Sedation
 
Sedation , analgesia & paralysis
Sedation , analgesia & paralysisSedation , analgesia & paralysis
Sedation , analgesia & paralysis
 
Icu delirium 11.8.19
Icu delirium 11.8.19Icu delirium 11.8.19
Icu delirium 11.8.19
 
Xolair and Cinqair for allergic asthma
Xolair and Cinqair for allergic asthmaXolair and Cinqair for allergic asthma
Xolair and Cinqair for allergic asthma
 
Sedation & Paralysis in ICU- DR.RAGHUNATH ALADAKATTI
Sedation & Paralysis in ICU- DR.RAGHUNATH   ALADAKATTISedation & Paralysis in ICU- DR.RAGHUNATH   ALADAKATTI
Sedation & Paralysis in ICU- DR.RAGHUNATH ALADAKATTI
 
Premedication mgmc (1)
Premedication mgmc (1)Premedication mgmc (1)
Premedication mgmc (1)
 
48078289 pharmacology-review-for-nurses
48078289 pharmacology-review-for-nurses48078289 pharmacology-review-for-nurses
48078289 pharmacology-review-for-nurses
 
Exciting recent advances in neurology
Exciting recent advances in neurologyExciting recent advances in neurology
Exciting recent advances in neurology
 
Sedation practices in ICU
Sedation practices in ICUSedation practices in ICU
Sedation practices in ICU
 
Parkinson disease Walid Reda Ashour Egypt
Parkinson disease  Walid Reda Ashour EgyptParkinson disease  Walid Reda Ashour Egypt
Parkinson disease Walid Reda Ashour Egypt
 

Viewers also liked

คู่มือประชาชน สำหรับการป้องกันน้ำท่วม54
คู่มือประชาชน สำหรับการป้องกันน้ำท่วม54คู่มือประชาชน สำหรับการป้องกันน้ำท่วม54
คู่มือประชาชน สำหรับการป้องกันน้ำท่วม54Aimmary
 
Cpg cancer pain_2556
Cpg cancer pain_2556Cpg cancer pain_2556
Cpg cancer pain_2556Aimmary
 
Hypothermic resuscitation sombat
Hypothermic resuscitation sombatHypothermic resuscitation sombat
Hypothermic resuscitation sombatAimmary
 
Hoi ching feng d20112053377 (el b01)
Hoi ching feng d20112053377 (el b01)Hoi ching feng d20112053377 (el b01)
Hoi ching feng d20112053377 (el b01)jcfeng16
 
Idioms 成语
Idioms 成语Idioms 成语
Idioms 成语jcfeng16
 
Final measle 30 07-11
Final measle 30 07-11Final measle 30 07-11
Final measle 30 07-11Aimmary
 
Prasit acute abdomen
Prasit acute abdomenPrasit acute abdomen
Prasit acute abdomenAimmary
 
Narain c-spine injury 2
Narain c-spine injury 2Narain c-spine injury 2
Narain c-spine injury 2Aimmary
 
Knowledge management in emergency medicine chatchai
Knowledge management in emergency medicine chatchaiKnowledge management in emergency medicine chatchai
Knowledge management in emergency medicine chatchaiAimmary
 
Thai hiv guideline2010
Thai hiv guideline2010Thai hiv guideline2010
Thai hiv guideline2010Aimmary
 
信心是生命的原动力
信心是生命的原动力信心是生命的原动力
信心是生命的原动力jcfeng16
 
Status epilepticus kong kiat
Status epilepticus kong kiatStatus epilepticus kong kiat
Status epilepticus kong kiatAimmary
 
Nath abdominal trauma
Nath abdominal traumaNath abdominal trauma
Nath abdominal traumaAimmary
 
Chitlada upper gi bleeding 2
Chitlada upper gi bleeding 2Chitlada upper gi bleeding 2
Chitlada upper gi bleeding 2Aimmary
 
Ep and haz_mat-chantana
Ep and haz_mat-chantanaEp and haz_mat-chantana
Ep and haz_mat-chantanaAimmary
 
Oa knee guideline
Oa knee guidelineOa knee guideline
Oa knee guidelineAimmary
 

Viewers also liked (18)

คู่มือประชาชน สำหรับการป้องกันน้ำท่วม54
คู่มือประชาชน สำหรับการป้องกันน้ำท่วม54คู่มือประชาชน สำหรับการป้องกันน้ำท่วม54
คู่มือประชาชน สำหรับการป้องกันน้ำท่วม54
 
Cpg cancer pain_2556
Cpg cancer pain_2556Cpg cancer pain_2556
Cpg cancer pain_2556
 
Ped hiv
Ped  hivPed  hiv
Ped hiv
 
Hypothermic resuscitation sombat
Hypothermic resuscitation sombatHypothermic resuscitation sombat
Hypothermic resuscitation sombat
 
Hoi ching feng d20112053377 (el b01)
Hoi ching feng d20112053377 (el b01)Hoi ching feng d20112053377 (el b01)
Hoi ching feng d20112053377 (el b01)
 
Idioms 成语
Idioms 成语Idioms 成语
Idioms 成语
 
Final measle 30 07-11
Final measle 30 07-11Final measle 30 07-11
Final measle 30 07-11
 
Prasit acute abdomen
Prasit acute abdomenPrasit acute abdomen
Prasit acute abdomen
 
Narain c-spine injury 2
Narain c-spine injury 2Narain c-spine injury 2
Narain c-spine injury 2
 
Knowledge management in emergency medicine chatchai
Knowledge management in emergency medicine chatchaiKnowledge management in emergency medicine chatchai
Knowledge management in emergency medicine chatchai
 
Thai hiv guideline2010
Thai hiv guideline2010Thai hiv guideline2010
Thai hiv guideline2010
 
信心是生命的原动力
信心是生命的原动力信心是生命的原动力
信心是生命的原动力
 
Hiv adult
Hiv adultHiv adult
Hiv adult
 
Status epilepticus kong kiat
Status epilepticus kong kiatStatus epilepticus kong kiat
Status epilepticus kong kiat
 
Nath abdominal trauma
Nath abdominal traumaNath abdominal trauma
Nath abdominal trauma
 
Chitlada upper gi bleeding 2
Chitlada upper gi bleeding 2Chitlada upper gi bleeding 2
Chitlada upper gi bleeding 2
 
Ep and haz_mat-chantana
Ep and haz_mat-chantanaEp and haz_mat-chantana
Ep and haz_mat-chantana
 
Oa knee guideline
Oa knee guidelineOa knee guideline
Oa knee guideline
 

Similar to Update tox 2010 june 2010 summon chomchai

Similar to Update tox 2010 june 2010 summon chomchai (20)

SerSyndrome
SerSyndromeSerSyndrome
SerSyndrome
 
ECT .pptx
ECT .pptxECT .pptx
ECT .pptx
 
Analgesic activity
Analgesic activityAnalgesic activity
Analgesic activity
 
Journal presentation on essential tremor
Journal presentation on essential tremorJournal presentation on essential tremor
Journal presentation on essential tremor
 
Hypoadrenalism
HypoadrenalismHypoadrenalism
Hypoadrenalism
 
case studies
case studies case studies
case studies
 
Approach to drug poisoning in adults by Dr Alaa Elmassry
Approach to drug poisoning in adults by Dr Alaa ElmassryApproach to drug poisoning in adults by Dr Alaa Elmassry
Approach to drug poisoning in adults by Dr Alaa Elmassry
 
Asthma_Medication.pdf
Asthma_Medication.pdfAsthma_Medication.pdf
Asthma_Medication.pdf
 
Rizk conscious-sedation
Rizk  conscious-sedationRizk  conscious-sedation
Rizk conscious-sedation
 
GENERALISED TONIC CLONIC SEIZURES
GENERALISED TONIC CLONIC SEIZURESGENERALISED TONIC CLONIC SEIZURES
GENERALISED TONIC CLONIC SEIZURES
 
Diagnóstico y manejo de los envenenamientos poco frecuentes
Diagnóstico y manejo de los envenenamientos poco frecuentesDiagnóstico y manejo de los envenenamientos poco frecuentes
Diagnóstico y manejo de los envenenamientos poco frecuentes
 
SEIZURE PPT.pptx
SEIZURE PPT.pptxSEIZURE PPT.pptx
SEIZURE PPT.pptx
 
Sedation
SedationSedation
Sedation
 
Status epilapticus
Status epilapticusStatus epilapticus
Status epilapticus
 
Seizure disorders
Seizure disordersSeizure disorders
Seizure disorders
 
ORGANOPHOSPHATE COMPOUND POISONING
ORGANOPHOSPHATE COMPOUND POISONINGORGANOPHOSPHATE COMPOUND POISONING
ORGANOPHOSPHATE COMPOUND POISONING
 
Stiripentol and Rufinamide
Stiripentol and RufinamideStiripentol and Rufinamide
Stiripentol and Rufinamide
 
Unusual Complication of OPC Poisoning
Unusual Complication of OPC PoisoningUnusual Complication of OPC Poisoning
Unusual Complication of OPC Poisoning
 
Postanesthetic care
Postanesthetic carePostanesthetic care
Postanesthetic care
 
Bronchial asthma pediatric
Bronchial asthma pediatricBronchial asthma pediatric
Bronchial asthma pediatric
 

More from Aimmary

งานเยี่ยมบ้าน
งานเยี่ยมบ้านงานเยี่ยมบ้าน
งานเยี่ยมบ้านAimmary
 
Smoking cessation1
Smoking cessation1Smoking cessation1
Smoking cessation1Aimmary
 
Heal the mind_while_facing_sickness
Heal the mind_while_facing_sicknessHeal the mind_while_facing_sickness
Heal the mind_while_facing_sicknessAimmary
 
Healed body healed_mind
Healed body healed_mindHealed body healed_mind
Healed body healed_mindAimmary
 
Ed building-asea ncommunity-2
Ed building-asea ncommunity-2Ed building-asea ncommunity-2
Ed building-asea ncommunity-2Aimmary
 
การให้ความรู้เรื่องเพศศึกษา
การให้ความรู้เรื่องเพศศึกษาการให้ความรู้เรื่องเพศศึกษา
การให้ความรู้เรื่องเพศศึกษาAimmary
 
Fooddiabe 03334
Fooddiabe 03334Fooddiabe 03334
Fooddiabe 03334Aimmary
 
143.irritable bowel syndrome (guideline 2012)
143.irritable bowel syndrome (guideline 2012)143.irritable bowel syndrome (guideline 2012)
143.irritable bowel syndrome (guideline 2012)Aimmary
 
24.hbv and hcv guideline 2012 (update)
24.hbv and hcv guideline 2012 (update)24.hbv and hcv guideline 2012 (update)
24.hbv and hcv guideline 2012 (update)Aimmary
 
Vis varicella-zoster
Vis varicella-zosterVis varicella-zoster
Vis varicella-zosterAimmary
 
Protect after morewater
Protect after morewaterProtect after morewater
Protect after morewaterAimmary
 
Lepto54 flood leaflet
Lepto54 flood leafletLepto54 flood leaflet
Lepto54 flood leafletAimmary
 
Lepto flood officer
Lepto flood officerLepto flood officer
Lepto flood officerAimmary
 

More from Aimmary (19)

Rdu book
Rdu bookRdu book
Rdu book
 
งานเยี่ยมบ้าน
งานเยี่ยมบ้านงานเยี่ยมบ้าน
งานเยี่ยมบ้าน
 
Smoking cessation1
Smoking cessation1Smoking cessation1
Smoking cessation1
 
Heal the mind_while_facing_sickness
Heal the mind_while_facing_sicknessHeal the mind_while_facing_sickness
Heal the mind_while_facing_sickness
 
Healed body healed_mind
Healed body healed_mindHealed body healed_mind
Healed body healed_mind
 
Ed building-asea ncommunity-2
Ed building-asea ncommunity-2Ed building-asea ncommunity-2
Ed building-asea ncommunity-2
 
การให้ความรู้เรื่องเพศศึกษา
การให้ความรู้เรื่องเพศศึกษาการให้ความรู้เรื่องเพศศึกษา
การให้ความรู้เรื่องเพศศึกษา
 
Fooddiabe 03334
Fooddiabe 03334Fooddiabe 03334
Fooddiabe 03334
 
143.irritable bowel syndrome (guideline 2012)
143.irritable bowel syndrome (guideline 2012)143.irritable bowel syndrome (guideline 2012)
143.irritable bowel syndrome (guideline 2012)
 
24.hbv and hcv guideline 2012 (update)
24.hbv and hcv guideline 2012 (update)24.hbv and hcv guideline 2012 (update)
24.hbv and hcv guideline 2012 (update)
 
Vis varicella-zoster
Vis varicella-zosterVis varicella-zoster
Vis varicella-zoster
 
Vis ipv
Vis ipvVis ipv
Vis ipv
 
Vis hpv
Vis hpvVis hpv
Vis hpv
 
Vis hib
Vis hibVis hib
Vis hib
 
Protect after morewater
Protect after morewaterProtect after morewater
Protect after morewater
 
Polio(1)
Polio(1)Polio(1)
Polio(1)
 
Lepto54 flood leaflet
Lepto54 flood leafletLepto54 flood leaflet
Lepto54 flood leaflet
 
Lepto flood officer
Lepto flood officerLepto flood officer
Lepto flood officer
 
Lepto
LeptoLepto
Lepto
 

Update tox 2010 june 2010 summon chomchai

  • 1. Summon Chomchai, MD, MPH Department of Preventive and Social Medicine Faculty of Medicine Siriraj Hospital, Mahidol University
  • 2. A 55 year-old-man  Found unconscious at home 1 hour PTA  1-2 hours PTA: He was seen eating Kratom and drank ethanol  At the ED:  P 96/min, R 12/min, BP 100/70 mmHg, O2 Sat 95% at room air  GCS: E1V1M1, pupils 2 mm  CVS and Chest: WNL, no secretion sound  Normal skin and mucosa  NS: Comatose, reflexes: 2+, plantar reflexes: fleoxor responses
  • 3. 0.4 mg of Naloxone was given with no response  He was treated with supportive (IV fluid, oxygen by canular and monitoring)  He woke up 10 hours after presentation  Admitted to ingested one handful of Kratom and one bottle of whiskey
  • 4.  Mithragyna Speciosa Korth  A plant used in Thailand and Malaysia  Scheduled to be illegal in Thailand, Malaysia, Myanmar and Australia  Increasing popularity as a drug of abuse  Clinical Toxicology (2008) 46, 146–152
  • 5.
  • 6. Mithragynine and 7-hydroxymithragynine  Unknown human pharmacokinetics  Agonists of delta and delta opioid receptors: Analgesia, euphoria and respiratory depression  Agonist to presynaptic alpha-2 adrenergic ,adenosine and serotonin receptors  Clinical Toxicology (2008) 46, 146–152
  • 7. Rat pharmacokinetic study: ◦ Peak plasma level:1.2-1.8 hour ◦ Elimination half-life: 3.86-9.43 hours ◦ Volume of distribution: 37.9-89.5 L/kg ◦ Clinical Toxicology (2008) 46, 146–152
  • 8. Dose-dependent neuropsychiatric symptoms  Onset 10-15 minutes; duration 1 hour ◦ Low dose: Stimulation: hypertension, tachycardia, tremor at low dose ◦ High dose: Opioid effects in high doses  Nausea, vomiting and diarrhea are commonly reported  Clinical Toxicology (2008) 46, 146–152
  • 9.
  • 10. It is used in workers in Thailand  In 2003, at least 221600 people were estimated to use Kratom in Thailand ◦ ~2% of Southern Thailand population  Purposes: ◦ Abuse: increase work endurance ◦ Medicinal use: treatment of chronic pain, cough, weight control ◦ Reports of using kratom for treating opioid withdrawal  Substance Use & Misuse (2006), 42:2145–2157
  • 11. Age of first uses: 20-40 years  Regular users: use because of condonation by family and peers as opposed to other ‘hard drugs’  Chewing leaves, drinking tea, smoking dry leaves  Very bitter taste; usually wash the taste with water, energizing beverages and palm juice  Adverse effects perceived by users: constipation, tremor and headahce  Substance Use & Misuse (2006), 42:2145–2157
  • 12. 61% of regular uses believe that they are addicted to Kratom  Withdrawal symptoms ◦ Inability to work ◦ Pain the the back, legs and muscles ◦ Crave  Other reported withdrawal symptoms: Yawn, rhinorrhea, myalgia, arthralgia and diarrhea  Substance Use & Misuse (2006), 42:2145–2157
  • 13. Rarely reported  2 case in Pubmed  1 case with unconsciousness and seizures  1 case of seizures  AMS for 30 hours  Confirmed mithragynine detection in urine by HPLC-ESI/MS/MS  No known long-term effects  J Med Toxicol. 2010 Apr 22.  Addiction. 2008 Jun;103(6):1048-50.
  • 14. Supportive and symptomatic care  Naloxine may be considered in cases with respiratory depression  J Med Toxicol. 2010 Apr 22.
  • 15. A 12-year-old girl was brought to the emergency room due to alteration of consciousness.  Her parents gave the history of using an over-the-counter antitussive drug, a small yellow coated tablet, for illicit purposes.  Her habit changed from gradual to progressive increase in the dosage of drug use, and from occasional with a few tablets at a time to daily doses in order to gain the desired effect of euphoria
  • 16. Six hours prior to hospitalization, the patient took 26 tablets of dextromethorphan (Romilar).  She reported of feeling sleepy, with nausea and abdominal discomfort.  Her father noted that she became increasingly confused and brought her to the emergency department (ED).  At the ED, vital signs BP117/70 mmHg, P 122 / min, R 20/ min, T38.2o C.  The patient appeared drowsy with Glascow coma scale of 15 (E4V5M6)  She was responsive and verbalized with notably slow speech.  Nystagmus was seen, Fundoscopic examination was normal  J Med Assoc Thai 2005; 88(Suppl 8): S242-5
  • 17. Non-opioid synthetic analog of codeine ◦ dextro-isomer of levorphanol  Actions are modulated by central sigma receptor binding sigma receptors  Unlike most opioids, the drug is devoid of activity at mu and delta receptors  Typical adult and pediatric doses (>12 years of age) of DM range from 60 to 120 mg/day in divided doses  At clinical doses, the drug produces no euphoriant, analgesic, or dependence-producing effects J Am Pharm Assoc. 2009;49:e20–e27
  • 18. Metablozied by CYP 2D6 to dextrophan ◦ noncompetitively antagonize the N-methyl-D-aspartate (NMDA) receptor and serotonin release ◦ Euphoria, hyperactivity and hallucination  In general, acute overdose of dextromethorphan causes nausea, vomiting, hyperexcitability, restlessness, hallucination, dizziness, drowsiness, ,lethargy, slurred speech, mydriasis, euphoria, tachycardia, hypertension and urinary retention.  The classical opioid effects such as respiratory depression and miosis are not commonly seen J Am Pharm Assoc. 2009;49:e20–e27
  • 19. J Am Pharm Assoc. 2009;49:e20–e27
  • 20.
  • 21. Minimal: 80-100 mg  Common: 200-400 mg  Heavy: 600-1500 mg  It may be ingested or snorted  Vivid visual hallucinations and complete body analgesia  Mild withdrawal symptoms that are similar to those of opiate withdrawal  http//:www.erowid.org/chemicals/dxm.
  • 22. Clinical diagnosis  Urine test: false positive for PCP  J Emerg Med. 2000;18:379-381.
  • 23. Gastric decontamination  Naloxone therapy: shown to be effective when used in children and for the specific indications of hyperexcitability, altered mental status or respiratory depression  Am J Emerg Med. 1991;9:237-238.
  • 24. A 18 y/o woman was brought in because of alteration of consciousness with a container of abamestin 1.8% W/V beside her  BP 102/60 mmHg, P 64/min, R 26/min, O2sat 90% @ room air  E1V1M2, pupils 3mm not reactive to light, normal skin and mucosa  CVS & Chest: WNL  Abdomen: Soft normal bowel sound  NS: Flaccid tone, reflexes: 1+ upper extremities, absent: lower extremities
  • 25. Abamectin is a potent antihelmintic, insecticide, and miticide  Derived from Strepto-myces avermitilis (species of Actinomyces)  Abamectin: a mixture of avermectins containing >80% avermectin B1a and <20% avermectin B1b ◦ Similar biological and toxicological properties
  • 26. Toxic effects of abamectin are usually seen after oral ingestions  May be absorbed dermally  Following their absorption, maximum  Serum concentrations peak 2.7 to 5 hours after oral dosing  Elimination half-life was 2.8 to10 hours among healthy volunteers ◦ Largely excreted into the bile and feces  Clin Toxicol (Phila). 2007;45(3):299-300.
  • 27. CNS symptoms such as incoordination, tremor, lethargy, excitation, and mydriasis via GABA agonistic effect  Deaths related to Abamectin ingestion are commonly a result of respiratory failure  From our experience: shock and status epilepticus  Clin Toxicol (Phila). 2007;45(3):299-300.
  • 28. Only one study in the literature by Chung et al  a significant correlation between the ingested abamectin dose and clinical severity ◦ For asymptomatic and mild poisoning, the average ingested dose was 23.0 mg/kg ◦ Average dose for severely poisoned patients was 100.7 mg/kg ~ 280 mL ◦ CNS and gastrointestinal effects:diarrhea, nausea, vomiting, AMS, dizziness and weakness  Ann Emerg Med. 1999 Jul;34(1):51-7.
  • 29. Airway protection  Hypotension: intravenous fluid and vasopressor  Clin Toxicol (Phila). 2007;45(3):299-300.
  • 30. Inhibitor of AchE  Bind to AchE and form a stable compound  Inactivate AchE molecule inactive  Once AchE molecules are unavailable, continued stimulation  cholinergic overstimulation  paralysis
  • 31.
  • 32. Signs and Symptoms  I. Muscarinic or parasympathetic symptoms  SLUDGE + 3 KILLER Bs  II. Nicotinic/ganglionic/NM symptoms  Muscle fasciculations, progressive paralysis and respiratory failure.  Hypertension, tachycardia, pupillary dilatation and pallor  III. CNS symptoms  Restlessness, tremor, confusion, ataxia, slurred speech and seizure.
  • 33. Clinical diagnosis  Cholinesterase level  Wide normal range  RBC cholinesterase  Specific  Hardly available  Plasma cholinesterase  More available  Non-specific
  • 34. Pupils  Sweating  Lung sounds: air entry, bronchospasm, secretion  Heart rate  Blood pressure Lancet. 2008 Feb 16;371(9612):597-607.
  • 35. Antagonizing muscarininc effects  Reactivating blocked cholinesterase  Treatment of muscle hyperstimulation/ seizures Lancet. 2008 Feb 16;371(9612):597-607.
  • 36. If the clinical presentation is not clear ◦ administer atropine 0.6– 1 mg  A marked increase in heart rate (more than 20–25 beats/min) and flushing of the skin suggest that the patient does not have significant cholinergic poisoning and further atropine is not required Lancet. 2008 Feb 16;371(9612):597-607.
  • 37. Atropine 1.8–3 mg (three to five 0.6 mg vials)  3-5 minutes after giving atropine, check the five markers of cholinergic poisoning(  A uniform improvement in most of the five parameters is required  The most important parameters are air entry on chest auscultation, heart rate, and blood pressure Lancet. 2008 Feb 16;371(9612):597-607.
  • 38. Clear chest on auscultation  Pupils with no wheeze  Lung sounds  Heart rate >80 beats/min  Pupils no longer pinpoint  Dry axillae  Systolic blood pressure >80 mmHg Indicators Pitfalls Critical Care 2004, 8:R391-R397
  • 39. With no improvement in 3-5 minutes: double dose the atropine until the goal is achieved  Continue doubling the dose each time that there is no response  From a review of 22 surviving patients with OP-poisoning and respiratory failure dose of atropine 1-75 mg(mean23.4 mg, 22.0sd) to clear the lungs, raise the pulse above 80bpm, and restore systolic blood pressure to more than 80 mmHg  Standard textbook therapy will take ◦ Up to 1380 mins to mean dose ◦ Up to 4440 mins to 75 mg dose  J Toxicol Clin Toxicol. 2004;42(6):865-75.  Crit Care. 2004 Dec;8(6):R391-7.
  • 40. Infusion of atropine  Rate per hour = 10-20% loading dose  Atropine intoxication: agitation, confusion, urinary retention, hyperthermia, bowel ileus and tachycardia  With intoxication: stop the atropine infusion and check every 30 minnutes  Once the atropine intoxication subsides restart the infusion at the rate 70-80% of the previous rate Lancet. 2008 Feb 16;371(9612):597-607.
  • 41. Oximes reactivate acetylcholinesterase inhibited by oganophosphorus  Despite the beneficial effects of pralidoxime, its effectiveness (and safety) has been much debated
  • 42. Meta-analysis of 7 studies of severe OP poisoning  382 patients  No significant risk or harm in terms of ◦ Overall mortality ◦ Need of respiratory support  Crit Care Med. 2006 Feb;34(2):502-10.
  • 43. Crit Care Med. 2006 Feb;34(2):502-10.
  • 44. Crit Care Med. 2006 Feb;34(2):502-10.
  • 45. A randomized controlled trial studied the effect of very-high-dose pralidoxime  Pralidoxime iodide (2 g loading dose, then 1 g either every hour or every 4 h for 48 h, then 1 g every 4 h until recovery)  200 patients with moderate organophosphorus poisoning  The high-dose regimen was associated with reduced case fatality (1% vs 8%; odds ratio [OR] 0·12, 95% CI 0·003–0·90),  Lancet. 2006 Dec 16;368(9553):2136-41.
  • 46. A prospective study on 802 patients self- poisoned with chlorpyrifos, dimethoate, or fenthion  Mortality: chlorpyrifos (8.0%), dimethoate (23.1%), fenthion (16.2%)  Endotracheal intubation: chlorpyrifos(15.0%), dimethoate (35.2%), fenthion (31.3%)  Patients poisoned by ◦ Diethyl OP pesticide (chlorpyrifos) responded well to pralidoxime ◦ Dimethyl OP (dimethoate, fenthion) responded poorly Lancet. 2005 Oct 22-28;366(9495):1452-9. Neth J Med. 2008 Apr;66(4):146-8.
  • 47. Dimethoate-poisoned patients ◦ Died sooner than other pesticides ◦ Often died from hypotensive shock  Fenthion poisoning initially caused few symptoms but many patients subsequently required intubation  Lancet. 2005 Oct 22-28;366(9495):1452-9.
  • 48. Lancet. 2005 Oct 22-28;366(9495):1452-9.
  • 49. Acephate  Chlorpyriphos Dialifos  Dicrotophos  Diazinon  Dichlofenthion  Dimethoate  Dioxathion  Fenchlorphos  Fonofos  Fenitrothion  Isazophos  Malathion  Isoxathion  Methamidophos  Mephosfolan  Phorate  Methylparathion  Phosalone  Mevinphos  Phoxim  Monocrotophos  Quinalphos  Temephos  Triazophos  Thiometon  Trichlorfon Dimethyl- Diethyl-
  • 50. A double-blind randomised placebo-controlled trial of pralidoxime chloride (2 g loading dose over 20 min, followed by a constant infusion of 0.5 g/h for up to 7 d)  235 patients with organophosphorus insecticide self-poisoning  Pralidoxime reactivated RBC acetylcholinesterase significantly  Mortality was nonsignificantly higher in treatnment group: 30/121 (24.8%) vs placebo18/114 (15.8%)  PLoS Med. 2009 Jun 30;6(6):e1000104.
  • 51. PLoS Med. 2009 Jun 30;6(6):e1000104.
  • 52. PLoS Med. 2009 Jun 30;6(6):e1000104.
  • 53. Pralidoximes be given to all symptomatic patients who need atropine or manifesting neuromuscular manifestations  Pralidoxime chloride ◦ Loading dose of 30 mg/kg intravenously over 20 minutes, followed by an infusion of 8 mg/kg/h ◦ Adults: 2 g loading dose followed by 500 mg/h.  Continue until recovery (12 hours after stopping administration of atropine or once butyrylcholinesterase increase) Lancet. 2008 Feb 16;371(9612):597-607.
  • 54. In the cholinergic nervous system, diazepam appears to decrease the synaptic release of Ach  In CNS diazepam causes hyperpolarization of neurons making them significantly less susceptible to cholinergically induced depolarization ◦ The ultimate result is cessation of propagation of convulsions  BMJ. 2007 Mar 24;334(7594):629-34.
  • 55. Overall effects of benzodiazepine: reducing anxiety and restlessness, reducing muscle fasciculation and seizures, controlling agitation  Indications: patients poisoned with OP whenever convulsions, agitation or pronounced muscle fasciculation are present  Doses: ◦ Diazepam 5-10 mg (0.05-0.3 mg/kg/dose) ◦ Midazolam 5-10 mg (0.15-0.2 mg/kg/dose)  Lancet. 2008 Feb 16;371(9612):597-607.
  • 56. A bipyridium herbicide  Toxicokinetics ◦ Rapid absorption: peak plasma level within 1-2 hours ◦ Incomplete absorption: 10-30% ◦ Distribute to tissues: Lung, Kidney ◦ Elimination: 90% eliminated within 12 -24 hours via kidney (half-life 10-12 hours)
  • 57.  Ingestion of paraquat leads to ◦ Generation of free oxygen radicals ◦ Lipid peroxidation ◦ Damaging cell membranes and leading to cell death.  Paraquat is actively taken up into type II pneumocytes and renal tubular cells.
  • 58.
  • 59. Mild poisoning: ◦ Local irritation: vomiting and diarhea ◦ Ingestion of less than 20 mg/kg of paraquat ion ◦ Full recovery without sequelae  Moderate to severe: ◦ Ingestion of 20-40 mg/kg of paraquat ion ◦ GI corrosion, acute tubular necrosis, hepatitis ◦ Delayed progressive pulmonary fibrosis ◦ Delayed mortality (1-4 weeks) from hypoxia ◦ Survivors may have gradual recovery of pulmonary functions over months to years
  • 60. Fulminant poisoning: ◦ Ingestion of more than 40 mg/kg of paraquat ion Usually die within 1-5 days ◦ GI ulceration ◦ Acute renal failure, myocardial damage, hepatic failure, pulmonary edema and hemorrhage ◦ Multiorgran failure, shock ◦ 100% mortality regardless of management
  • 61. Hart’s Nomogram  Plasma paraquat level drawn within 28 hours  Those with level 3 mg/L at anytime: 100% mortality  No fulminant poisoning:  2.0 mg/L at 4 hr  0.3 mg/L at 10 hr  0.1 mg/L at 24 hr Eddleston M, Wilks MF, Buckley NA. Qjm 2003;96(11):809-24. 61
  • 62. Method Sensivitity Specificity Positive Negative predictive predictive value value Proudfoot/ 0.79 0.89 0.92 0.73 Scherrmann Hart (50% 0.77 0.92 0.94 0.71 survival line) Jones(p=0.5) 0.70 0.93 0.94 0.67
  • 63. In a study with 53 cases of paraquat poisoning  All patients with urinary paraquat concentrations less than 1 µg/ml(no color change-pale blue), within 24 h of ingestion, survived  Cases with results more than ++ (navy blue; >10 µg/ml) within 24 h following ingestion have a high probability of death  Hum Toxicol1987 Jan;6(1):91-3.
  • 64.
  • 65.
  • 66. A study using sodium dithionite test for plasma paraquat as a qualitative test in 233 paraquat poisoning patients  Blood samples were drawn within 12 hours  Detection limits: concentration ≥ 2 mg/L  Levels above 2 mg/L are associated with high mortality in many studies  Patients with a plasma paraquat level < 2.0 mg/L have the potential for recovery with vigorous treatment  Sensitivity 0.67  Specificity 1.0  Positive predictive value 1.0 ◦ Am J Med Sci2009 Nov;338(5):373-7.
  • 67. Urine should be tested serially for 24 h after ingestion  An early urinary semiquantitative testing may underestimate the amount of paraquat systemically absorbed  Crit Rev Toxicol. 2008;38(1):13-71.
  • 68. Although quantitative plasma paraquat concentrations have a greater predictive value, qualitative urine and plasma may contribute to a more rapid evaluation of prognosis with more availability ◦Am J Med Sci2009 Nov;338(5):373-7.
  • 69. Activated charcoal/ Fuller’s earth/ bentonite  Improve survival in animal studies  Equivocal efficacy in animal studies  Adsorbent therapy alone has never shown increase survival in human  Meredith TJ, Vale JA. Hum Toxicol 1987;6(1):49-55. 69
  • 70. Significant clearance and improved survival shown in canine models loaded with LD50 and LD100 dose.  No systematic study showing that hemodialysis or hemoperfusion is efficacious in human  Possible cause of failure:  Relatively small amount cleared  While renal function is still intact, external clearance is smaller than renal clearance  When renal failure develops, pulmonary uptake has already occurred.  Recommendation: perform charcoal hemoperfusion only if it can be started within 4 hours.  Med J Aust 1991;154(9):617-22. 70
  • 71. The most widely investigated and applied aspect of specific management is immunosuppressive therapy, especially the regimen consisitng of ◦ Cyclophosphamide ◦ Corticosteriods  Concepts: Reduction of pulmonary inflammation and fibrosis using antiinflammatory and immunosuppressive therapy
  • 72.  Regimen: cyclophosphamide 5 mg/kg/day and dexamethasone 24 mg/day for 14 days  Total cases = 72  Mortality: treated 20/72(27.8)% vs historical control 42/61(68.9%)  Lancet. 1986 May 17;1(8490):1117-20.  Another study  Survival: treated 20/31(64.5%) vs historical control 9/14(64.3%)  Hum Exp Toxicol. 1992 Mar;11(2):129-34.
  • 73.  A single-blinded randomized clinical trial in 142 paraquat-poisoned patients, pulse therapy reduced mortality in moderate to severe poisoning from 53/65(81.5%) to 38/56(67.9%)  Pulse therapy included 1. 15 g/kg/day of cyclophosphamide for 2 days 2. 1 g/day of methylprednisolone for 3 days  All patients also received dexamethasone 30mg/day for 14 days  Am J Respir Crit Care Med. 1999 Feb;159(2):357-60.
  • 74. N = 23 cases of paraquat poisoned patients with predictive mortality > 50% but < 90% by plasma level  Initial pulse therapy: cyclophosphamide (15 mg/kg/day, i.v., 2 days) and methylprednisolone (1 g/day i.v., 2 days) Followed by dexamethasone 5 mg, i.v., every 6 h until PaO2 > 80 mmHg  Randomized cases for repeated pulse therapy if PaO2 was < 60 mmHg: 3 days of methylprednisolone and 1 day of cyclophosphamide  Mortality rate: ◦ control 6/7 = 85.7% ◦ Study 5/16 = 31.3% (p=0.027)  Crit Care Med. 2006 Feb;34(2):368-73.
  • 75.  A retrospective study in 54 cases  Significantly higher survival with suppression of leucocyte or neutrophil counts by at least 10% after the initiation of immunosuppressive ◦ Journal Of the Chinese Medical Association2009;72(9 supplement):S20-1.
  • 76. 12 studies using immunosuppressive therapy in the management of paraquat poisoning ◦ Four non-randomized ◦ Six non-randomized comparing historical controls ◦ Two randomized controlled trials  The relative risk of immunosuppressive therapy in decreasing mortality with paraquat poisoning ◦ 0.55 (95 % CI 0.39- 0.77) for the non-randomized studies (comparing historical controls) ◦ 0.6 (95 % CI 0.27-1.34) for randomized controlled studies  Singapore Med J2007 Nov;48(11):1000-5.
  • 77. Systematic review  3 RCT  Total cases : 164 moderate to severe cases  Inclusion criteria: Urine navy blue or drak blue and/ or plasma level in the range of mortality 50-90%  Interventions: IV cyclophosphamide and dexamethasone  Main outcomes: mortality at the end of follow up (at least 30 days post ingestion)  Results: RR 0.72 (95% CI 0.59 to 0.89)  Cochrane Database Syst Rev. 2010 Jun 16;6:CD008084.
  • 78. Cochrane Database Syst Rev. 2010 Jun 16;6:CD008084.
  • 79.